May 31, 2012
FDA Approves RXi Drug For Clinical Trials
RXi Pharmaceuticals Corp. of Worcester has received the green light from the U.S. Food and Drug Administration (FDA) to start clinical trials for a drug that would reduce scarring from surgery.
"RXi's next-generation RNAi platform has shown great promise," said President and CEO Dr. Geert Cauwenbergh. "As we aggressively pursue the potential of this compound for this condition with major social impact, we will also continue to work to create long-term shareholder value."
Read more
With Clinical Trial Ongoing, RXi Losses Climb
RXi Awarded Funding For Cancer Therapy
WBJ Web Partners
Most Recent
Most Recent
0 Comments